Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy (NCT06065371)

🧪 Interventions in This Study

• Capecitabine (DRUG)
• Sacituzumab govetican (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Henry Ford Cancer-Detroit — Detroit, Michigan

📞 Contact the Study Coordinator

Phone: (313) 920-4051

Email: mdiab2@hfhs.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Gastrointestinal Cancer

• Advancing Nursing Practices in Hospital Oncology Care — New York, New York
• Avatrombopag vs. Placebo for CIT in GI Malignancies — Miami, Florida
• A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) — New Haven, Connecticut
• Dyadic Sleep Study — Coral Gables, Florida
• EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. — Cleveland, Ohio
• Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™) — Los Angeles, California

Explore by condition: All Gastrointestinal Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.